MannKind Triples (Its Cash)!

MannKind (NASDAQ: MNKD  ) is in a waiting game.

The biotech resubmitted its application to the Food and Drug Administration, responding to issues brought up by the rejection in 2011. The next known catalyst is a potential -- I'd argue expected -- approval of its inhaled insulin product Afrezza. Unfortunately, that's still months away, in April 2014.

Fortunately, it looks like MannKind will be able to get to that point and beyond. The biotech more than tripled its cash reserves during the quarter from $28.5 million at the end of the second quarter to $93.8 million at the end of September. And after the quarter ended, the company received another $45 million from warrants that were exercised.

MannKind looks like it has plenty of cash to get to the FDA decision next year, given its guidance of burning between $30 million and $36 million per quarter. The dilution has been costly to shareholders, but getting to the end of the marathon is the ultimate goal.

Billion-dollar questions remains unanswered
Investors looking for an update on the bigger question of who will eventually market Afrezza didn't get any meaningful update on the process of looking for a marketing partner.

When might the results of the search be announced?
"We are not yet prepared to suggest the date for completion," CEO and Chairman Alfred Mann said on the call.

Well, is it going to be before or after the FDA decision in April?
"I would not make a commentary on that one because then I'm speculating," President and COO Hakan Edstrom said.

What kind of structure are we looking at, because it'll affect the cash situation?
"I think it'd be premature to just speculate on the terms of that kind of a partnership," CFO Matthew Pfeffer said.

Have a backup plan if you can't find a global partner?
"We have several very, very aggressive potential partners and a number -- quite a large number of others that have inquired. But we haven't really followed up with them," Mann said, referring to the potential to divvy out regions to multiple regional partners.

Guessing game continues
From the sound of it -- and it's best to take Mann with a grain of salt -- a partnership is likely, but the timing and structure of the deal (or deals), will likely determine which way the stock moves on the news.

If MannKind can land a big pharma partner with a substantial amount of upfront cash, it'll be a huge endorsement. I continue to think the diabetes partnership of Bristol-Myers Squibb (NYSE: BMY  ) and AstraZeneca (NYSE: AZN  ) would be a good fit. The companies bought diabetes specialist Amylin together and now have a handful of diabetes drugs that they co-market. Having two companies to share the long-term investment should make the risk more palatable.

If MannKind can't snag Bristol-Myers Squibb and AstraZeneca or some other big pharma and it has to settle for some small specialty pharma, investors aren't going to be happy.

At this point, an investment in MannKind is a bet that Mann can follow through on his hype. When and how that's going to happen is still unknown.

Back to waiting.

These biotechs already have partners
The best way to play the biotech space is to find companies that shun the status quo and instead discover revolutionary, groundbreaking technologies. In the Motley Fool's brand-new FREE report "2 Game-Changing Biotechs Revolutionizing the Way We Treat Cancer," find out about a new technology that big pharma is endorsing through partnerships, and the two companies that are set to profit from this emerging drug class. Click here to get your copy today.


Read/Post Comments (2) | Recommend This Article (6)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On November 05, 2013, at 5:13 PM, theeseer wrote:

    Brian you should re think your "hype" accusation for the CEO of MNKD. This guy is a medical doctor who made billions from developing the insulin pump. He has put his money where his mouth and expertise is by developing a more efficient insulin and delivery device good for type 1 and 2 diabetes. He has submitted a revised FDA 3 application of 2000 pages!

    Do you have any idea of what the absorption rate of this new type of insulin is versus existing brands and methods? I doubt it. That alone is worth a bundle. Next time dig a little deeper. Its not hype when you have the goods and expertise.

    Hype is hedge fund guy with no experience in retail ruining a retail chain called Sears.

  • Report this Comment On November 06, 2013, at 12:39 PM, StockWatcher wrote:

    I have watched you repeatedly beat this stock down. I am not sure what you have against the company of the CEO or maybe its just the product but I am thinking you should investigate a little more. The CEO is the guy that invented the insulin pump.... Why you ask because he cares about patients and the hardships they go through. Second the product itself is revolutionary and has the ability to change the lives of many diabetics and their ties to pain injections and refrigeration needs. It is also much faster and longer lived in it's reactions. Get a clue this is a product that not only is needed but wanted and is well researched. Live with diabetes and see if you aren't ready to look for something better. I am sure that there are millions of patients that are counting on this to pass FDA.

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2713858, ~/Articles/ArticleHandler.aspx, 9/20/2014 6:16:28 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement